Feedback
Myeloid Malignancies Mutation Panel by Next Generation Sequencing
2011117
Ordering Recommendation

Assess for single gene mutations, including substitutions and insertions and deletions that may have diagnostic, prognostic, and/or therapeutic significance in acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, or MDS/MPN overlap disorders such as chronic myelomonocytic leukemia.

Mnemonic
MYE NGS
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
12-14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) OR bone marrow (EDTA). 
Specimen Preparation
Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) OR Transport 3 mL bone marrow. (Min: 1 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Serum, plasma or tissue. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens. 
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
The diagnosis under consideration is required information to order this test. Genes tested: ASXL1, ASXL2, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CEBPA, CSF3R, DNMT1, DNMT3A, EED, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, HNRNPK, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, NOTCH1, NPM1, NRAS, NSD1, PHF6, PRPF40B, PRPF8, PTPN11, RAD21, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2
Components
Component Test Code*Component Chart NameLOINC
2011118Myeloid Malignancy Proposed Diagnosis
2011119Myeloid Malignancies Panel Specimen31208-2
2011120Myeloid Malignancies Panel Interp35474-6
2011121EER Myeloid Malignancies Panel by NGS11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Acute myeloid leukemia, AML
  • ASXL1, ASXL2, BCOR, BCORL1, BRAF, BRINP3/FAM5C, CALR, CBL, CEBPA, CSF3R, DNMT1, DNMT3A
  • Atypical chronic myelogenous leukemia
  • Chronic eosinophilic leukemia not otherwise specified
  • Chronic myelogenous leukemia, BCR-ABL1 positive
  • Chronic myelomonocytic leukemia, CMML
  • Chronic neutrophilic leukemia
  • EED, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, HNRNPK, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT
  • Eosinophilia
  • Juvenile myelomonocytic leukemia, JMML
  • KMT2A/MLL, KRAS, LUC7L2, MAP2K1, MPL, NOTCH1, NPM1, NRAS, NSD1, PHF6, PRPF40B, PRPF8, PTPN11
  • Mastocytosis
  • Myelodysplastic syndrome with isolated del(5q)
  • Myelodysplastic syndromes
  • Myelodysplastic/Myeloproliferative neoplasm
  • Myeloproliferative neoplasm
  • Myeloproliferative neoplasm, essential thrombocythemia
  • Myeloproliferative neoplasm, polycythemia vera
  • Myeloproliferative neoplasm, primary myelofibrosis
  • RAD21, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, SUZ12
  • Refractory anemia with excess blasts, RAEB
  • Refractory anemia with ring sideroblasts associated with marked thrombocytosis, RARS-T
  • Refractory anemia with ring sideroblasts, RARS
  • Refractory cytopenia with multilineage dysplasia, RCMD
  • Refractory cytopenia with unilineage dsysplasia, RCUD
  • TET2, TP53, U2AF1, U2AF2,WT1, ZRSR2